Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243721 | 0.85 | HRH4 (0.56) | HRH4PYGL | |
| SCHEMBL14143106 | 0.84 | HRH4 (0.58) | HRH4PYGL | |
| SCHEMBL1977879 | 0.80 | HRH4 (0.55) | HRH4PYGL | |
| SCHEMBL1244777 | 0.76 | ALOX15 (0.55) | HRH4PYGL | |
| SCHEMBL603529 | 0.73 | HRH4 (1.00) | HRH4 | |
| SCHEMBL2333687 | 0.70 | DAO (0.71) | HRH4PYGL | |
| SCHEMBL6633345 | 0.69 | PYGL (1.00) | PYGL | |
| SCHEMBL8268450 | 0.68 | HRH4 (0.43) | HRH4PYGL | |
| SCHEMBL11607578 | 0.63 | DAO (0.39) | — | |
| SCHEMBL1244253 | 0.63 | DAO (0.51) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130178453-A1 | Cannabinoid Agonists | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178453-A1 | Cannabinoid Agonists | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178453-A1 | Cannabinoid Agonists | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2011100359-A1 | CANNABINOID AGONISTS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| EP-1633709-A1 | ANTI-DIABETIC AGENTS | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1620427-A1 | CARBOXAMIDE DERIVATIVES AS ANTI-DIABETIC AGENTS | Pfizer Products Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-6992092-B2 | substituted N-(indole-2-carbonyl)amides; antiischemic, anticholesterol, hypoglycemic, hypotensive agents; 5-chloro-1H-indole-2-carboxylic acid-[5-(1,2-dihydroxy-1-methyl-ethyl)-3-ethoxy-pyridin-2-yl]-amide | PFIZER INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040229916-A1 | Anti-diabetic agents | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| WO-2004096768-A1 | ANTI-DIABETIC AGENTS | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220229-A1 | insulin resistance; central nervous system disorders; vision defects; anticholesterol agents;antilipemic agents; antiischemic agents | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
| WO-2004092158-A1 | CARBOXAMIDE DERIVATIVES AS ANTI-DIABETIC AGENTS | PFIZER PRODUCTS INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229916-A1 | Anti-diabetic agents | GPR119, SLC5A1, GLP1R | HRH4 2854/4885PYGL 140/4885 |
| US-20040220229-A1 | insulin resistance; central nervous system disorders; vision defects; anticholesterol agents;antilipemic agents; antiischemic agents | IRS1, INSR, GPR119 | HRH4 2848/4885PYGL 97/4885 |
| US-20130178453-A1 | Cannabinoid Agonists | CNR2, CNR1, GPR18 | HRH4 144/4885PYGL 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.